Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2016

View Archived Issues

Mitsubishi Tanabe profiles pipeline progress of second quarter of fiscal 2016

Lundbeck updates key developments of third quarter 2016

AZD-8931 does not improve progression-free survival in wild-type colorectal cancer patients

NIH award supports TherapyX's testing of IL10-NanoCap

NICE recommends Eisai's eribulin for breast cancer

Ascend Biopharmaceuticals reports interim results of phase I/IIa study on ASN-002

Study finds pharmacokinetic equivalence between Neulasta pegfilgrastim and Mylan/Biocon biosimilar

FDA accepts BLA for human rabies immunoglobulin

First-in-human study of Mucosis' SynGEM begins

GeoVax and ViaMune to codevelop cancer immunotherapy program

The Medicines Company discontinues development of MDCO-216

Amgen presents pipeline highlights of third quarter 2016

Vertex Pharmaceuticals reports positive phase III results on Orkambi

CHERISH study of Spinraza in later-onset SMA meets primary endpoint

TGFB1 may be behind coronary artery disease with glatiramer acetate treatment

FDA grants several orphan drug designations to APX-001

Scientists develop a new animal model for BBSOAS

H. Lundbeck patents PDE1 inhibitors

Guangdong Zhongsheng Pharmaceutical describes thromboxane synthase inhibitors

Guangzhou Maxinovel Pharmaceuticals develops ALK tyrosine kinase receptor inhibitors

Shire offers overview of third quarter 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...